Targeted Drug Delivery: Reduce Cancer Side Effects
- As cancer diagnoses continue to rise, innovative treatments are crucial.
- Globally, 1 in 4 people will develop cancer, spurring the need to improve existing treatments like chemotherapy and radiotherapy, which can harm healthy tissues.
- Targeted therapies aim to increase treatment efficacy, shorten recovery, and improve patients' quality of life by reducing the necessary medication and protecting healthy tissue.
Radioligand therapy is revolutionizing cancer treatment, promising fewer side effects and a better patient experience. This cutting-edge approach uses targeted radioligands to precisely attack cancerous cells, offering hope for those battling this pervasive disease. The radiopharma market is booming, with projections soaring to $26.5 billion by 2031 due to its effectiveness in shrinking tumors and improving patients’ quality of life. However, logistical and safety challenges around radioactive materials still limit its reach.News Directory 3 notes the notable investment in this space, with major pharma players acquiring radiopharmaceutical companies to fuel innovation. Discover how these innovative therapies are increasing treatment efficacy, while shortening recovery times.What does the future hold for radioligand therapy?
Radioligand Therapy: A New Frontier in Targeted Cancer Treatment
Table of Contents
June 16, 2025
As cancer diagnoses continue to rise, innovative treatments are crucial. radioligand therapy, a targeted approach, is gaining traction for its potential to minimize side effects and enhance the patient experience. This therapy uses radioligands – microscopic particles combining a radioactive isotope and a cell-targeting ligand – to precisely target cancerous cells after intravenous injection.
Expanding Cancer Treatment Options
Globally, 1 in 4 people will develop cancer, spurring the need to improve existing treatments like chemotherapy and radiotherapy, which can harm healthy tissues. Immunotherapies offer a less invasive approach by stimulating the body’s immune system. however, targeted drug therapies, including radioligands, promise even greater precision.
Targeted therapies aim to increase treatment efficacy, shorten recovery, and improve patients’ quality of life by reducing the necessary medication and protecting healthy tissue. Radioligands have attracted meaningful investment, with the radiopharma market projected to grow from $9.1 billion in 2023 to $26.5 billion in 2031, representing a 14% compound annual growth rate.
Other targeted methods include SonoTarg’s ultrasound-activated microbubble solution and Pfizer’s antibody-drug conjugates (ADCs). ADCs, which combine antibodies and cytotoxic drugs, have been in clinical trials as Pfizer’s first FDA-approved ADC in 2000.
Implementing new therapies like radioligands requires updating care pathways and reimbursement models, along with managing radioactive elements safely. Medtech and pharma companies can play a key role in ensuring safe supply and integration of radioligands into cancer treatment.
Prioritizing Safety
Logistical and safety barriers currently limit the reach of radioligands. Addressing the management of radioactive properties is crucial for wider adoption. Many facilities lack the equipment to handle radioactive substances, complicating transport, delivery, and storage. Doses must be carefully calibrated due to the constant decay of radioactive compounds, frequently enough requiring adjustments based on patient biometrics.
Extensive safety training and protective equipment are essential, and radiation safety standards vary by location, necessitating specific guidance. Sustainability is also a concern, as radioligand shipping containers are not typically reused or recycled.
Hospitals often have radio-pharmacy and radio-oncology departments, but community clinics may need partnerships to upskill staff and update procedures. Licensed waste management services can handle off-site decay, sharing risk and improving accessibility.
Building trust
For radioligands to be widely adopted, healthcare professionals must trust the treatment and understand its use. Clinical workflows will vary, and proper training is essential to build confidence among staff and patients. Medtech and pharma leaders can contribute to training programs, fostering trust in both the treatment and the ability to administer it effectively. Patients also need assurance of safety and insurance coverage.
Enhancing Accessibility
Radioligand therapy, such as Pluvicto for prostate cancer, involves injections every six weeks, followed by a two-day isolation period. This is often less disruptive than the side effects of conventional treatments.
Democratizing access requires a distributed model supported by partnerships. Pharma and medtech companies can collaborate with hospitals and clinics to develop standard operating procedures (SOPs) that prioritize patient accessibility. Reducing travel burdens and ensuring agile supply chains are also critical to avoid wasted doses. External specialists like radio-pharmacists and physicists can facilitate this process.
Accessibility is linked to new payment models. Choice payment models (APMs) reward healthcare providers for cost savings and efficient care,incentivizing a shift from volume-based to outcomes-based models. Medtech and pharma companies can help providers access these rewards by creating cost-effective therapeutic solutions.
Sustaining investment
Medical advancements often originate in smaller startups or academic teams. larger companies are investing heavily in radiopharmaceuticals, with acquisitions like Eli Lilly’s $1.4 billion purchase of Point Biopharma and AstraZeneca’s $2.4 billion acquisition of Fusion Pharmaceuticals.
These investments are yielding results. Lutathera, a radioligand and radionuclide therapy, treats gastroenteropancreatic neuroendocrine tumors (GEP-NETs), while Xofigo, another radioligand for prostate cancer, is used when other therapies fail.
The Future of Cancer Treatment
In the next decade, radioligand therapy could significantly reduce side effects and improve recovery rates across various cancers. Tailoring treatments to individual conditions and diverse clinical teams will maximize their impact. By acting as partners and advisors, medtech and pharma organizations can foster the safety, accessibility, and trust needed to transform cancer care.